Showing results (581-590 of 834) with videos related to

Sort By:
Pageof 84
Cardiovascular Diabetology|September 16, 2023
Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney diseaseJ David Smeijer, Donald E Kohan, Peter Rossing, et al.
Acta Diabetologica|August 31, 2020
Serum glycated albumin predicts all-cause mortality in dialysis patients with diabetes mellitus: meta-analysis and systematic review of a predictive biomarkerSidar Copur, Dimitrie Siriopol, Baris Afsar, et al.
ESC Heart Failure|July 29, 2024
Coronary microvascular dysfunction and left heart filling pressures in patients with type 2 diabetesEmil Wolsk, Mikkel Jürgens, Morten Schou, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 14, 2022
Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)Jennifer B Green, Amy K Mottl, George Bakris, et al.
JACC. Cardiovascular Imaging|March 10, 2015
Global longitudinal strain is not impaired in type 1 diabetes patients without albuminuria: the Thousand & 1 studyMagnus Thorsten Jensen, Peter Sogaard, Henrik Ullits Andersen, et al.
Diabetes, Obesity & Metabolism|July 3, 2023
The effects of empagliflozin on measured glomerular filtration rate and estimated extracellular and plasma volumes in patients with type 2 diabetesMikkel Jürgens, Morten Schou, Philip Hasbak, et al.
American Heart Journal|May 9, 2025
Effect of once-weekly subcutaneous semaglutide on arterial inflammation in people with type 2 diabetes and cardiovascular disease using PET-MRI: Primary results of a randomized, double-blind, placebo-controlled trialStefan James, Andreas Dyreborg Christoffersen, Jens-Peter David, et al.
Diabetes|July 10, 2021
The Low-Expression Variant of FABP4 Is Associated With Cardiovascular Disease in Type 1 DiabetesEmma H Dahlström, Jani Saksi, Carol Forsblom, et al.
The Lancet. Diabetes & Endocrinology|November 11, 2018
Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trialDick de Zeeuw, Ronny W Renfurm, George Bakris, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 26, 2026
A Hierarchical Composite Endpoint for Chronic Kidney Disease Progression in Patients with Focal Segmental GlomerulosclerosisHiddo J L Heerspink, Dustin J Little, Samvel B Gasparyan, et al.
Pageof 84